Drugs / E-CEL UVEC
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04190862 | Jan 2020 → Sep 2026 overdue | anal fistula | Weill Medical College of Cornell University | Recruiting | No outcome recorded |
| Phase 1 | NCT04057833 | Nov 2019 → Oct 2026 expected | muscular atrophy, rotator cuff syndrome | Hospital for Special Surgery, New York | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E-CEL UVEC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04057833 ↗ |
| Modality | Cell therapy | “Cell Therapy” NCT04057833 ↗ |
| Route | Other | “Local implantation of E-CEL UVEC cells at the supraspinatus tendon repair site” NCT04057833 ↗ |